When biotech executive Matthew Panuwat bought options on a rival drug company’s stock, he earned a hearty sum of $120,000. But the SEC says he committed insider trading, even though he didn’t buy his employer’s stock and was not privy to inside information about the company on which he bet.
Free Trial
Register for free to keep reading.
To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.
- Unlimited access to industry insights
- Stay on top of key rules and regulatory changes with our Rules Navigator
- Ad-free experience with no distractions
- Regular podcasts from trusted external experts
- Fresh compliance and regulatory content every day
